Genetics Disparity Rally with Dr. Keith Crawford

Описание: Genetic testing for prostate cancer is transforming how the disease is detected, treated, and managed, especially for Black men who face a higher risk of aggressive prostate cancer. This educational presentation explains how DNA, genes, and inherited mutations influence prostate cancer risk and how genomic testing and precision medicine are shaping the future of treatment.

Using clear, relatable examples, the speaker breaks down complex topics like germline mutations, somatic mutations, BRCA gene changes, and PARP inhibitor therapies. The discussion also highlights why understanding your genetic profile can guide screening decisions, identify targeted treatment options, and help family members better understand their own cancer risks.

Key Topics Covered:

• How DNA, genes, and mutations influence cancer development
• The difference between germline mutations (inherited) and somatic mutations (acquired)
• Why genetic testing can help assess prostate cancer risk
• The role of BRCA1 and BRCA2 gene mutations in prostate cancer
• How PARP inhibitor therapies target DNA repair pathways in cancer cells
• The importance of genomic testing and next-generation sequencing (NGS)
• Why genetic testing may guide personalized prostate cancer treatment
• How inherited mutations may impact family members’ cancer risk

Key Takeaway:

Prostate cancer is one of the most heritable cancers, with genetic factors accounting for a significant portion of risk. Black men face higher diagnosis and mortality rates, making awareness of genetic testing, early screening, and clinical trial participation critical steps toward improving outcomes and advancing equitable cancer care.